Article · Wikipedia archive · Last revised Jul 4, 2026

7-Fluorotryptamine

7-Fluorotryptamine (7-FT) is a serotonin receptor modulator and weak GPRC5A agonist of the tryptamine family. It is the 7-fluoro derivative of tryptamine. The drug is a low-potency agonist of the orphan receptor GPRC5A, with an EC50Tooltip half-maximal effective concentration of 7,200 nM. In addition to its GPRC5A agonism, 7-fluorotryptamine interacts with other receptors, such as the serotonin 5-HT4 receptor. Derivatives of 7-fluorotryptamine have been described. 7-Fluorotryptamine was first described in the scientific literature by 1979. Its GPRC5A agonism was first described in 2023.

Last revised
Jul 4, 2026
Read time
≈ 2 min
Length
377 w
Citations
10
Source
Wikipedia ↗
7-Fluorotryptamine
Clinical data
Other names7-F-T; 7-Fluoro-T; 7-FT
Drug classSerotonin receptor modulator; GPRC5A agonist
ATC code
  • None
Identifiers
  • 2-(7-fluoro-1H-indol-3-yl)ethanamine
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.197.219
Chemical and physical data
FormulaC10H11FN2
Molar mass178.210 g·mol−1
3D model (JSmol)
  • C1=CC2=C(C(=C1)F)NC=C2CCN
  • InChI=1S/C10H11FN2/c11-9-3-1-2-8-7(4-5-12)6-13-10(8)9/h1-3,6,13H,4-5,12H2
  • Key:QRAWNNQNLQPNIZ-UHFFFAOYSA-N

7-Fluorotryptamine (7-FT) is a serotonin receptor modulator and weak GPRC5A agonist of the tryptamine family.12 It is the 7-fluoro derivative of tryptamine.2 The drug is a low-potency agonist of the orphan receptor GPRC5A, with an EC50Tooltip half-maximal effective concentration of 7,200 nM.123 In addition to its GPRC5A agonism, 7-fluorotryptamine interacts with other receptors, such as the serotonin 5-HT4 receptor.2 Derivatives of 7-fluorotryptamine have been described.4 7-Fluorotryptamine was first described in the scientific literature by 1979.5 Its GPRC5A agonism was first described in 2023.2

See also

See also

References

References

  1. Huang WC, Lin WT, Hung MS, Lee JC, Tung CW (January 2024). "Decrypting orphan GPCR drug discovery via multitask learning". Journal of Cheminformatics. 16 (1) 10. doi:10.1186/s13321-024-00806-3. PMC 10804799. PMID 38263092. During the review process of the manuscript, two agonistic ligands of 7-fluorotryptamine and tryptamine were reported for the orphan GPRC5A [43]. With a Ts of 6.2%, a good MSE of 1.46 was obtained using the MTL-AG-ATG-FS model. Detailed prediction is listed in Additional file 1: Table S5. For the promising agonist of 7-fluorotryptamine, its predicted EC50 is 2.4 μM, which is close to the experimental value of 7.2 μM [43]. This provides a successful example for predicting ligands of an orphan receptor.
  2. Zhao X, Stein KR, Chen V, Griffin ME, Lairson LL, Hang HC (October 2023). "Chemoproteomics reveals microbiota-derived aromatic monoamine agonists for GPRC5A". Nature Chemical Biology. 19 (10): 1205–1214. doi:10.1038/s41589-023-01328-z. PMID 37248411.
  3. Hamrick SK, Thompson M, Drake LY, Venkatachalem S, Pabelick CM, Prakash YS (1 May 2025). "Class C GPRC5A in Human Airway Smooth Muscle". American Journal of Respiratory and Critical Care Medicine. 211 (Supplement_1) A3084. doi:10.1164/ajrccm.2025.211.Abstracts.A3084. ISSN 1073-449X.
  4. Kawase M, Sinhababu AK, McGhee EM, Milby T, Borchardt RT (August 1990). "Synthesis and biological evaluation of 4-fluoro-, 7-fluoro-, and 4,7-difluoro-5,6-dihydroxytryptamines". Journal of Medicinal Chemistry. 33 (8): 2204–2211. doi:10.1021/jm00170a026. PMID 2100997.
  5. Treimer JF, Zenk MH (November 1979). "Purification and properties of strictosidine synthase, the key enzyme in indole alkaloid formation". European Journal of Biochemistry. 101 (1): 225–233. Bibcode:1979EJBio.101..225T. doi:10.1111/j.1432-1033.1979.tb04235.x. PMID 510306.
External links